Project Number 3R01AG032611-05S1 Agency/Funding Organization NIA Funding Year 2013 View Full Project Details for CLEARANCE AND IN VIVO DETECTION OF TAU PATHOLOGY Research Categorization Primary Disease / Condition Alzheimer's Disease Frontotemporal Dementia CADRO Category A. Molecular Pathogenesis and Physiology of Alzheimer's Disease and Alzheimer's Disease-related Dementias (AD/ADRDs) 2. Tau b. Tau Phosphorylation, Metabolism, and Assembly Researcher and Organization Principal Investigator SIGURDSSON, EINAR M Principal Investigator First Name EINAR M Principal Investigator Last Name SIGURDSSON Awardee Organization NEW YORK UNIVERSITY SCHOOL OF MEDICINE Awardee State New York, N.Y. Contact PI Country United States Project Detail Funding Opportunity Announcement RFA-OD-13-199: NIH ADMINISTRATIVE SUPPLEMENTS TO RECOVER LOSSES DUE TO HURRICANE SANDY UNDER THE DISASTER RELIEF APPROPRIATIONS ACT NON-CONSTRUCTION (ADMIN SUPP) FY Overall Cost $329,443 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official MILLER, MARILYN Related Resources Repository [AlzPED] Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy [AlzPED] Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. [AlzPED] Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. Patent Immunological targeting of pathological Tau proteins
